At the time of writing, Roivant Sciences Ltd [ROIV] stock is trading at $11.37, up 2.16%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ROIV shares have gain 1.43% over the last week, with a monthly amount drifted -3.64%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Roivant Sciences Ltd [NASDAQ: ROIV] stock has seen the most recent analyst activity on February 15, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $17. Previously, Piper Sandler started tracking the stock with Overweight rating on January 05, 2024, and set its price target to $20. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $14 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $17 on October 17, 2023. BofA Securities initiated its recommendation with a Neutral and recommended $10.50 as its price target on June 08, 2023. JP Morgan started tracking with a Overweight rating for this stock on October 27, 2022, and assigned it a price target of $7. In a note dated May 23, 2022, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
For the past year, the stock price of Roivant Sciences Ltd fluctuated between $9.69 and $13.06. Currently, Wall Street analysts expect the stock to reach $15.5 within the next 12 months. Roivant Sciences Ltd [NASDAQ: ROIV] shares were valued at $11.37 at the most recent close of the market. An investor can expect a potential return of 36.32% based on the average ROIV price forecast.
Analyzing the ROIV fundamentals
According to Roivant Sciences Ltd [NASDAQ:ROIV], the company’s sales were 125.68M for trailing twelve months, which represents an -87.94% plunge. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 34.48%, Pretax Profit Margin comes in at 37.82%, and Net Profit Margin reading is 38.27%. To continue investigating profitability, this company’s Return on Assets is posted at 0.78, Equity is 0.83 and Total Capital is 0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.23 points at the first support level, and at 11.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.47, and for the 2nd resistance point, it is at 11.56.
Ratios To Look Out For
It is important to note that Roivant Sciences Ltd [NASDAQ:ROIV] has a current ratio of 10.43. Also, the Quick Ratio is 10.43, while the Cash Ratio stands at 3.54. Considering the valuation of this stock, the price to sales ratio is 65.86, the price to book ratio is 1.62 and price to earnings (TTM) ratio is 2.01.
Transactions by insiders
Recent insider trading involved Venker Eric, President & COO, that happened on Jan 21 ’25 when 100000.0 shares were sold. Officer, Venker Eric completed a deal on Jan 21 ’25 to buy 100000.0 shares. Meanwhile, Director Roivant Sciences Ltd. bought 16.85 million shares on Jan 13 ’25.
